Skytrofa 9.1 mg Powder and solvent for solution for injection
Authorisation EU/1/21/1607/007 · Ascendis Pharma Endocrinology Division A/S
- Licence holder
- Ascendis Pharma Endocrinology Division A/S (all products →)
- Active substances
- Lonapegsomatropin, Somatropin
- Clinical trials
- 6 clinical trials →
- Dosage form
- Powder and solvent for solution for injection
- Route of administration
- Subcutaneous use
- ATC code
- H01AC09
- First authorised
- 11/01/2022
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Full application (Article 8(3) of Directive No 2001/83/EC)
Lonapegsomatropin: supply and approvals
9 authorised products on the HPRA list contain Lonapegsomatropin. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 21 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 21 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 21 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
Somatropin: supply and approvals
37 authorised products on the HPRA list contain Somatropin. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- Norditropin FlexPro / Norditropin NordiFlex: Shortage resolved, first published 5 Dec 2023
- US shortage (FDA)
- Somatropin Injection: resolved, updated 13 Nov 2026
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 21 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 1607. It has been authorised for 4 years (since 11 January 2022). The HPRA list does not say whether it is on sale.
Other medicines with Lonapegsomatropin in Ireland
8 other products on the HPRA list contain Lonapegsomatropin, from 1 licence holder; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Skytrofa 11 mg Powder and solvent for solution for injection | Ascendis Pharma Endocrinology Division A/S | Centralised EU authorisation | Not stated |
| Skytrofa 13.3 mg Powder and solvent for solution for injection | Ascendis Pharma Endocrinology Division A/S | Centralised EU authorisation | Not stated |
| Skytrofa 3 mg Powder and solvent for solution for injection | Ascendis Pharma Endocrinology Division A/S | Centralised EU authorisation | Not stated |
| Skytrofa 3.6 mg Powder and solvent for solution for injection | Ascendis Pharma Endocrinology Division A/S | Centralised EU authorisation | Not stated |
| Skytrofa 4.3 mg Powder and solvent for solution for injection | Ascendis Pharma Endocrinology Division A/S | Centralised EU authorisation | Not stated |
| Skytrofa 5.2 mg Powder and solvent for solution for injection | Ascendis Pharma Endocrinology Division A/S | Centralised EU authorisation | Not stated |
| Skytrofa 6.3 mg Powder and solvent for solution for injection | Ascendis Pharma Endocrinology Division A/S | Centralised EU authorisation | Not stated |
| Skytrofa 7.6 mg Powder and solvent for solution for injection | Ascendis Pharma Endocrinology Division A/S | Centralised EU authorisation | Not stated |
Other medicines with Somatropin in Ireland
36 other products on the HPRA list contain Somatropin, from 7 licence holders; 17 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| GENOTROPIN 12 mg powder and solvent for solution for injection | Pfizer Healthcare Ireland Unlimited Company | National authorisation (PA) | Marketed |
| GENOTROPIN 5.3 mg powder and solvent for solution for injection, with preservative | Pfizer Healthcare Ireland Unlimited Company | National authorisation (PA) | Marketed |
| GENOTROPIN MINIQUICK 0.6 mg powder and solvent for solution for injection | Pfizer Healthcare Ireland Unlimited Company | National authorisation (PA) | Marketed |
| GENOTROPIN MINIQUICK 0.2 mg powder and solvent for solution for injection | Pfizer Healthcare Ireland Unlimited Company | National authorisation (PA) | Marketed |
| GENOTROPIN MINIQUICK 0.4 mg powder and solvent for solution for injection | Pfizer Healthcare Ireland Unlimited Company | National authorisation (PA) | Marketed |
| GENOTROPIN MINIQUICK 0.8 mg powder and solvent for solution for injection | Pfizer Healthcare Ireland Unlimited Company | National authorisation (PA) | Marketed |
| GENOTROPIN MINIQUICK 1.0 mg powder and solvent for solution for injection | Pfizer Healthcare Ireland Unlimited Company | National authorisation (PA) | Marketed |
| GENOTROPIN MINIQUICK 1.2 mg powder and solvent for solution for injection | Pfizer Healthcare Ireland Unlimited Company | National authorisation (PA) | Marketed |
| GENOTROPIN MINIQUICK 1.4 mg powder and solvent for solution for injection | Pfizer Healthcare Ireland Unlimited Company | National authorisation (PA) | Marketed |
| GENOTROPIN MINIQUICK 1.6 mg powder and solvent for solution for injection | Pfizer Healthcare Ireland Unlimited Company | National authorisation (PA) | Marketed |
| GENOTROPIN MINIQUICK 1.8 mg powder and solvent for solution for injection | Pfizer Healthcare Ireland Unlimited Company | National authorisation (PA) | Marketed |
| GENOTROPIN MINIQUICK 2.0 mg powder and solvent for solution for injection | Pfizer Healthcare Ireland Unlimited Company | National authorisation (PA) | Marketed |
The licence holder
Ascendis Pharma Endocrinology Division A/S holds 9 products on the HPRA list, with 2 different active substances; 0 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.